Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on … Ended

2024-513027-16-00 Resectable mucosal melanomas 4 2018-05-28
A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended

2024-510913-13-00 Previously Untreated Metastatic or Unresectable Melanom 10 2018-05-18
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Lymphoma of B-cell origin 7 2018-05-16
MB-CART19.1 r/r CD19+ BCM Ended

2024-513334-38-00 Refractory/relapsed B-NHL 1 2018-05-15
REGOMUNE : A phase I/II study of Regorafenib plus Avelumab in solid tumors Ended

2023-509500-15-00 Adult patients with advanced or metastatic solid tumors 9 2018-05-03
Talquetamab (GPRC5D and CD3 antibody) in Relapsed or Refractory Multiple Myeloma Ended

2023-504581-29-00 Multiple myeloma 7 2018-04-26
A Study of Glofitamab (RO7082859) and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patient… Ended

2023-505222-34-00 Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma 7 2018-04-23
A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-… Ended

2023-503469-49-00 Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic L 5 2018-04-19
A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Res… Ended

2023-508726-10-00 Hepatocellular Carcinoma 5 2018-03-28
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
START : Study on Androgen Receptor and Triple Negative Breast Cancer Ended

2024-516638-36-00 Triple-negative androgen receptor positive (molecular a 4 2018-03-14
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Adv… Ended

2024-516477-73-00 Bladder cancer and kidney cancer 3 2018-03-07
Trial on efficacy and safety of vaccination of newly diagnosed glioblastoma patients with the patient's own immune cells. Ended

2024-514820-18-00 newly diagnosed glioblastoma 4 2018-03-07
Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy. Ended

2023-509004-15-00 Patients with non-small cell lung cancer (NSCLC). 10 2018-02-20
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combinatio… Ended

2024-514205-60-00 Triple Negative Breast Cancer 4 2018-02-15
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended

2024-513070-21-00 Relapsed Acute Lymphoblastic Leukemia (ALL) 4 2018-02-15
Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (with and without Bor… Ended

2023-506110-43-00 Multiple Myeloma 9 2018-01-25
A study to investigate the clinical benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone in adults with newl… Ended

2024-514417-34-00 Cancer 5 2017-12-14
Darolutamide vs ADT in hormone naïve Pca Ended

2024-510840-30-00 Hormone Naive Prostate Cancer 4 2017-12-01
This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, … Ended

2024-512212-21-00 Advanced hepatocellular carcinoma (HCC) 5 2017-11-28
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended

2023-510444-21-00 Neuroendocrine tumours of gastroenteric or pancreatic o 5 2017-11-24
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Breast cancer 5 2017-11-21
Myechild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Fin… Ended

2024-516112-21-00 Newly diagnosed acute myeloid leukaemia (AML), high ris 5 2017-11-20
AAS-Lynch - Assessment of the effect of a daily chemoprevention by aspirin low-dose of new or recurrent colorectal adenomas in patients with… Ended

2024-516601-23-00 Colorectal adenomas 5 2017-11-14